Terms: = Skin cancer AND B2M, P61769, 567, ENSG00000166710
94 results:
1. Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Versluis JM; Hoefsmit EP; Shehwana H; Dimitriadis P; Sanders J; Broeks A; Blank CU
Cancer Immunol Immunother; 2024 Jan; 73(2):28. PubMed ID: 38280045
[TBL] [Abstract] [Full Text] [Related]
2. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma.
Ellebaek E; Khan S; Bastholt L; Schmidt H; Haslund CA; Donia M; Svane IM
Eur J Cancer; 2024 Feb; 198():113476. PubMed ID: 38171116
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Utility of Melanoma Sentinel Lymph Node Biopsy Nomograms.
Drebin HM; Hosein S; Kurtansky NR; Nadelmann E; Moy AP; Ariyan CE; Bello DM; Brady MS; Coit DG; Marchetti MA; Bartlett EK
J Am Coll Surg; 2024 Jan; 238(1):23-31. PubMed ID: 37870230
[TBL] [Abstract] [Full Text] [Related]
4. Antitumor Immune Responses in b2m-Deficient cancers.
Torrejon DY; Galvez M; Abril-Rodriguez G; Campbell KM; Medina E; Vega-Crespo A; Kalbasi A; Comin-Anduix B; Ribas A
Cancer Immunol Res; 2023 Dec; 11(12):1642-1655. PubMed ID: 37801341
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
6. Survival Outcomes and Prognostic Factors of Dermatofibrosarcoma Protuberans: A Population-Based Retrospective Cohort Analysis.
Chen S; Xiong L; Zhao L; Li Y; Li L
Dermatol Surg; 2023 Sep; 49(9):825-831. PubMed ID: 37384896
[TBL] [Abstract] [Full Text] [Related]
7. Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.
Draghi A; Presti M; Jensen AWP; Chamberlain CA; Albieri B; Rasmussen AK; Andersen MH; Crowther MD; Svane IM; Donia M
Clin Cancer Res; 2023 Oct; 29(19):3937-3947. PubMed ID: 37126006
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract] [Full Text] [Related]
9. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal.
Magro CM; Kalomeris T; Roberts A
Ann Diagn Pathol; 2023 Apr; 63():152101. PubMed ID: 36634549
[TBL] [Abstract] [Full Text] [Related]
10. Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling.
Barber J; Al-Majdoub ZM; Couto N; Howard M; Elmorsi Y; Scotcher D; Alizai N; de Wildt S; Stader F; Sepp A; Rostami-Hodjegan A; Achour B
Eur J Pharm Sci; 2023 Mar; 182():106375. PubMed ID: 36626943
[TBL] [Abstract] [Full Text] [Related]
11. Induction of Immune-Stimulating Factors and Oncolysis Upon p14
Mendonça SA; Antunes F; Cerqueira OLD; Del Valle PR; Hunger A; Oliveira PVS; Brito B; Costanzi-Strauss E; Strauss BE
DNA Cell Biol; 2023 Jun; 42(6):274-288. PubMed ID: 36576491
[TBL] [Abstract] [Full Text] [Related]
12. Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.
Samlowski W; Silver MA; Hohlbauch A; Zhang S; Scherrer E; Fukunaga-Kalabis M; Krepler C; Jiang R
Future Oncol; 2022 Oct; 18(33):3755-3767. PubMed ID: 36346064
[TBL] [Abstract] [Full Text] [Related]
13. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M; Presti M; Sztupinszki Z; Jensen AWP; Draghi A; Chamberlain CA; Schina A; Yde CW; Wojcik J; Szallasi Z; Crowther MD; Svane IM; Donia M
Cancer Immunol Res; 2022 Oct; 10(10):1254-1262. PubMed ID: 35969233
[TBL] [Abstract] [Full Text] [Related]
14.
Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
Front Immunol; 2022; 13():725679. PubMed ID: 35844619
[TBL] [Abstract] [Full Text] [Related]
15. Accelerated epigenetic aging in newborns with Down syndrome.
Xu K; Li S; Muskens IS; Elliott N; Myint SS; Pandey P; Hansen HM; Morimoto LM; Kang AY; Ma X; Metayer C; Mueller BA; Roberts I; Walsh KM; Horvath S; Wiemels JL; de Smith AJ
Aging Cell; 2022 Jul; 21(7):e13652. PubMed ID: 35661546
[TBL] [Abstract] [Full Text] [Related]
16. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
[TBL] [Abstract] [Full Text] [Related]
17. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of Immediate Breast Reconstruction Outcomes in Patients With and Without Prior Cosmetic Breast Surgery.
Fiser CK; Kronenfeld JP; Liu SN; Goel N; Kassira W; Oeltjen JC; Kesmodel SB
Clin Breast Cancer; 2022 Feb; 22(2):136-142. PubMed ID: 34481753
[TBL] [Abstract] [Full Text] [Related]
19. Perilesional sun damage as a diagnostic clue for pigmented actinic keratosis and Bowen's disease.
Weber P; Sinz C; Rinner C; Kittler H; Tschandl P
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2022-2026. PubMed ID: 34146354
[TBL] [Abstract] [Full Text] [Related]
20. A reliable set of reference genes to normalize oxygen-dependent cytoglobin gene expression levels in melanoma.
De Backer J; Maric D; Bosman M; Dewilde S; Hoogewijs D
Sci Rep; 2021 May; 11(1):10879. PubMed ID: 34035373
[TBL] [Abstract] [Full Text] [Related]
[Next]
